Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma


Study Number
601720
Phase
Expanded Access
Purpose

Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma. You can access GSK's Compassionate Use (Expanded Access) Request Portal via https://gsk-cu-portal.idea-point.com.

Full Title

Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody

ClinicalTrials.Gov ID
NCT03763370

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.